Landiolol in Mitral Valve Surgery

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.

Also called NCT06793670

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
Università Vita-Salute San Raffaele (from the registry)
Registry
  • NCT NCT06793670
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06793670. Randomized; double masking; primary purpose prevention. Start 2025-01-28 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Landiolol in Mitral Valve Surgery
Acronym
LUNA
Condition
Cardiac Failure
Condition
Low Cardiac Output Syndrome
Intervention (Drug)
Landiolol
Intervention (Drug)
Placebo
Lead sponsor
Università Vita-Salute San Raffaele (class: other)

Record details

Record id
cardio:ct-nct06793670
Content hash
7ed623549f90c22e87edfd79e235a02e13329a91a6bf640d3b06597993ac78da